425: Avere Therapeutics Presents Promising Oral IL-23RA Data

Avere Therapeutics, in conjunction with NextCure, has published corporate presentation detailing the development of AVR-001, a once-weekly oral IL-23 receptor antagonist for inflammatory diseases.

Summary

• Avere Therapeutics is developing AVR-001, a once-weekly oral peptide targeting the IL-23 receptor, for inflammatory diseases like psoriasis, psoriatic arthritis, and inflammatory bowel disease.
• Phase 1 data for AVR-001 in psoriasis shows encouraging proof of concept, with a half-life supporting once-weekly dosing and meaningful improvements in PASI scores and key biomarkers.
• AVR-001 demonstrated comparable efficacy to Icotyde (a daily oral IL-23RA) in Phase 1 studies, with a potentially more convenient dosing regimen.
• The company's mission is to deliver IL-23RA efficacy and safety in a convenient weekly oral dose.
• Avere is also involved in a proposed merger with NextCure, Inc., with financings expected to fund AVR-001 through key clinical milestones.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, highlighting promising preclinical and early clinical data for a novel therapeutic candidate, balanced by the inherent risks of drug development and a pending merger.

Positives

• AVR-001 has a half-life of approximately 100 hours, supporting a convenient once-weekly oral dosing regimen.
• Early Phase 1 data shows meaningful improvements in PASI scores and key biomarkers for psoriasis.
• AVR-001 demonstrated comparable efficacy to Icotyde in Phase 1 studies, suggesting potential for a best-in-class profile.
• The lead indication, psoriasis, is a large and growing market ($32B+), with expansion opportunities into psoriatic arthritis and inflammatory bowel diseases.
• The management team has a strong track record in drug development and company building, including experience at Gilead and Akero Therapeutics.
• The IND for AVR-001 is in effect, and Phase 2b studies for psoriasis and ulcerative colitis are anticipated.

Negatives

• The filing contains numerous disclaimers regarding the preliminary nature of the data and the risks associated with drug development.
• Cross-trial comparisons are necessary due to differing trial designs, patient populations, and endpoints between AVR-001 Phase 1 and Icotyde Phase 3 studies.
• One serious adverse event (myocardial infarction) was reported in a Phase 1 patient with multiple cardiovascular risk factors, though deemed unrelated.
• The intellectual property landscape for IL-23 is described as crowded, with potential for infringement claims, although the company believes it has freedom to operate.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
• Preclinical and clinical data generated by third parties outside the U.S. may not be directly predictive of U.S. clinical trial results or regulatory outcomes.
• The company is under no obligation to update or keep current the information contained in the presentation.
• There is no assurance that the assumptions or estimates regarding market data and competitive position are accurate.
• The proposed merger with NextCure is subject to various closing conditions, including stockholder approval and financing completion, which may not be met.
• The combined company's ability to manage expenses and obtain sufficient additional capital to advance product candidates is uncertain.

Future Outlook

Financings are expected to fund AVR-001 through key value-generating clinical proof-of-concept data, including Phase 2b psoriasis and ulcerative colitis readouts, and the initiation of Phase 3 psoriasis trials.

Management Comments

• "Icotyde has the potential to be one of our largest products ever."
• "Our mission is to deliver IL-23RA efficacy & safety in a convenient weekly oral dose."
• "Avere is developing potentially best-in-class oral therapies for the treatment of psoriasis, IBD, & PsA."
• "Once-weekly dosing would lead to a huge improvement in patient compliance."
• "It would be a huge improvement to have once a week dosing to reduce the daily thoughts of psoriasis management."

Industry Context

StockSavvy.ai notes that the development of oral IL-23 receptor antagonists (IL-23RAs) is a significant area of focus in the inflammatory disease space, with recent approvals like Icotyde validating the target. Avere's AVR-001 aims to differentiate itself with a convenient once-weekly oral formulation, addressing a key limitation of current daily oral therapies.

Comparison to Industry Standards

• AVR-001 Phase 1 data shows absolute PASI score changes at Week 4 comparable to Icotyde's Phase 3 results (-44% to -46% for AVR-001 vs. -44% for Icotyde).
• At Week 8, AVR-001 showed deepening PASI score changes (-66% to -72%) despite treatment cessation after Week 4, which is also comparable to Icotyde's Week 8 results (-66%).
• PASI 75 response rates at Week 8 for AVR-001 (53% to 59%) are comparable to Icotyde's Phase 3 results (47%).
• Reductions in IL-17A and hBD-2 biomarkers for AVR-001 at Week 4 are consistent with Icotyde's Phase 3 data.
• The market for psoriasis is projected to grow to $44B by 2030, and the IBD market to $39B by 2030, indicating significant market potential for effective therapies.
• The oral IL-23RA market is nascent, with Icotyde's 2026 approval, and has blockbuster potential, with projected peak sales for first-generation oral IL-23RAs estimated at over $8B in psoriasis alone.

Legal Proceedings

• The filing mentions that the company believes it will have freedom to operate regarding intellectual property, but acknowledges the IL-23 IP space is crowded with potential for infringement claims by third parties.

Stakeholder Impact

• Shareholders of NextCure may see their investment diluted or their ownership stake change due to the proposed merger and financing.
• Patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease could benefit from a more convenient and effective oral treatment option.
• Investors in the proposed private placement of Avere Therapeutics securities will gain exposure to a drug candidate in the inflammatory disease space.
• The successful development and commercialization of AVR-001 could significantly impact the market for inflammatory disease treatments.

Next Steps

• Initiate Phase 2b psoriasis study.
• Initiate Phase 2b ulcerative colitis study.
• Initiate Phase 3 psoriasis trials.
• Complete the proposed merger with NextCure, Inc.
• Complete the associated financing transaction.

Key Dates

Recommendation

The filing presents promising early-stage data for AVR-001 and a strong management team, suggesting significant potential. However, the inherent risks of drug development, the preliminary nature of the data (Phase 1), the need for further clinical validation (Phase 2b and 3), and the uncertainties surrounding the pending merger with NextCure warrant a cautious 'hold' recommendation. Investors should await further clinical data and clarity on the merger's completion before considering a more aggressive stance.

Keywords

AVR-001, IL-23RA, Psoriasis, Inflammatory Bowel Disease, Psoriatic Arthritis, Oral Therapy, Biomarkers, Clinical Trials